GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis.
Zhang. Ju J; Guan. Xiangfeng X; Kong. Mowei M; Xia. Meng M; Yu. Yang Y; Zhang. Chunxiang C
Key Findings
- GLP‑1RAs and tirzepatide cut all‑cause mortality (RR 0.88) and cardiovascular death (RR 0.88) in people with heart or kidney disease
- Overall, they didn’t significantly reduce heart‑failure hospitalizations, but obese patients saw a benefit (interaction P = 0.02)
- Safety profile is good – fewer serious and cardiac adverse events versus placebo
Practical Outcomes
- If you’re an obese biohacker with cardiovascular or renal issues, adding tirzepatide could meaningfully lower your risk of death and possibly heart‑failure hospital stays. Use standard dosing protocols, monitor weight and kidney function, and stay aware of the generally mild side‑effect profile.
Summary
This review shows that tirzepatide (and similar GLP‑1 drugs) not only helps control blood sugar but also cuts the risk of dying from any cause or from heart problems in people with heart or kidney disease, especially if they’re overweight. It may also lower the chance of ending up in the hospital for heart‑failure among obese patients.
Abstract
Cardiovascular disease (CVD) and chronic kidney disease (CKD) frequently coexist, with obesity and type 2 diabetes (T2D) being major contributors to adverse outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide have shown cardiorenal benefits beyond glycemic control, but their efficacy across metabolic phenotypes remains unclear. This review was prospectively registered in PROSPERO (CRD420251088042). PubMed, Embase, Web of Science, and Cochrane Library were searched (January 2015-July 2025) for RCTs comparing GLP-1RAs or tirzepatide with placebo in patients with cardiovascular or renal disease. Subgroup analyses were performed according to T2D and obesity status. A total of 18 RCTs (n = 97,800) involving eight GLP-1RAs and tirzepatide were included, primarily enrolling patients with established cardiovascular or renal disease. GLP-1RAs significantly reduced the risk of the primary composite outcome (RR 0.88, 95 % CI 0.84-0.91, P < 0.001). GLP-1RAs and tirzepatide also significantly reduced the risk of death from any cause (RR 0.88, 95 % CI 0.84-0.92, P < 0.001), and death from cardiovascular causes (RR 0.88, 95 % CI 0.83-0.93, P < 0.001). Although the overall effect of GLP-1RAs on hospitalization for heart failure was not statistically significant (RR 0.92, 95 % CI 0.78-1.08), a potential benefit was observed in obese patients (P for interaction = 0.02), warranting further investigation. GLP-1RAs showed favorable overall safety profile, with a lower incidence of serious adverse events (RR 0.93, 95 % CI 0.89-0.99, P = 0.01) and cardiac adverse events (RR 0.90, 95 % CI 0.85-0.96, P < 0.01) compared with placebo. In patients with cardiovascular or renal disease, GLP-1RAs and tirzepatide provide consistent cardiovascular and renal protection, with a possible benefit in reducing hospitalization for heart failure among individuals with obesity.
Study Information
pubmed
2025
2025-11-08T00:00:00.000Z
10.1016/j.metabol.2025.156433
66